Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Current Hepatology Reports
Published in: Current Hepatology Reports 1/2024

04-03-2024 | Portal Hypertension | Review

Systemic Disease and Portal Hypertension

Authors: Talal Khurshid Bhatti, Paul Y. Kwo

Published in: Current Hepatology Reports | Issue 1/2024

Login to get access

Abstract

Purpose of Review

The development of portal hypertension is typically a consequence of liver cirrhosis due mainly to primary liver disorders, whereas non-cirrhotic portal hypertension (NCPH) can be a complication of systemic, primarily extrahepatic diseases. Our purpose was to review the various systemic disorders leading to portal hypertension and provide a pathway for diagnosis and management.

Recent Findings

Non-cirrhotic portal hypertension is a heterogeneous group of liver disorders primarily of vascular origin that may manifest as portal hypertension. The diagnosis of NCPH in the setting of systemic diseases is challenging and a liver biopsy may be required to confirm the diagnosis. Etiologies include those of vascular origin, autoimmune disorders, drug exposures, and infections.

Summary

Complications of portal hypertension in the setting of systemic diseases are similar to patients having cirrhosis and should be addressed similarly while addressing the underlying systemic disorder if possible
Literature
1.
Schouten JN, Garcia-Pagan JC, Valla DC, Janssen HL. Idiopathic noncirrhotic portal hypertension. Hepatology. 2011;54(3):1071–81.PubMedCrossRef
2.
Gracia-Sancho J, Marrone G, Fernández-Iglesias A. Hepatic microcirculation and mechanisms of portal hypertension. Nat Rev Gastroenterol Hepatol. 2019;16(4):221–34.PubMedCrossRef
3.
Intagliata NM, Caldwell SH, Tripodi A. Diagnosis, development, and treatment of portal vein thrombosis in patients with and without cirrhosis. Gastroenterology. 2019;156(6).
4.
Simonetto DA, Liu M, Kamath PS. Portal hypertension and related complications :diagnosis and management. Mayo Clin Proc. 2019;94(4):714–26.PubMedCrossRef
5.
Khanna R, Sarin SK. Idiopathic portal hypertension and extrahepatic portal venous obstruction. Hepatol Int. 2018;12(Suppl 1):148–67.PubMedCrossRef
6.••
Da BL, Surana P, Kapuria D, Vittal A, Levy E, Kleiner DE, Koh C, Heller T. Portal pressure in noncirrhotic portal hypertension: to measure or not to measure. Hepatology. 2019;70(6):2228–30. Of major importance: This study reported in a large cohort of individuals with non-cirrhotic portal hypertension that portal pressures as assessed by HVPH are not typically elevated and also do not correlate with complications of portal hypertension. They suggest that at obtaining a liver biopsy percutaneously may be an appropriate strategy in this population.PubMedCrossRef
7.
Eapen CE, Nightingale P, Hubscher SG, et al. Non-cirrhotic intrahepatic portal hypertension: associated gut diseases and prognostic factors. Dig Dis Sci. 2011;56(1):227–35.PubMedCrossRef
8.
Sharma P, Agarwal R, Dhawan S, Bansal N, Singla V, Kumar A, Arora A. Transient elastography (fibroscan) in patients with non-cirrhotic portal fibrosis. J Clin Exp Hepatol. 2017;7(3):230–4.PubMedPubMedCentralCrossRef
9.
10.
Verheij J, Schouten JN, Komuta M, et al. Histological features in western patients with idiopathic non-cirrhotic portal hypertension. Histopathology. 2013;62(7):1083–91.PubMedCrossRef
11.
Lee H, Rehman AU, Fiel MI. Idiopathic noncirrhotic portal hypertension: an appraisal. J Pathol Transl Med. 2016;50(1):17–25.PubMedCrossRef
12.
Nayak NC, Jain D, Saigal S, Soin AS. Non-cirrhotic portal fibrosis: one disease with many names? An analysis from morphological study of native explant livers with end stage chronic liver disease. J Clin Pathol. 2011;64(7):592–8.PubMedCrossRef
13.
Hillaire S, Bonte E, Denninger MH, et al. Idiopathic non-cirrhotic intrahepatic portal hypertension in the west: a re-evaluation in 28 patients. Gut. 2002;51(2):275–80.PubMedPubMedCentralCrossRef
14.
De Gottardi A, Rautou PE, Schouten J, Rubbia-Brandt L, Leebeek F, Trebicka J, Murad SD, Vilgrain V, Hernandez-Gea V, Nery F, Plessier A. Porto-sinusoidal vascular disease: proposal and description of a novel entity. Lancet Gastroenterol Hepatol. 2019;4(5):399–411.PubMedCrossRef
15.
Cerda Reyes E, González-Navarro EA, Magaz M, Muñoz-Sánchez G, Diaz A, Silva-Junior G, et al. Autoimmune biomarkers in porto-sinusoidal vascular disease: potential role in its diagnosis and pathophysiology. Liver Int. 2021;41(9):2171–8.PubMedCrossRef
16.
Sarin SK, Kapoor D. Non-cirrhotic portal fibrosis: current concepts and management. J Gastroenterol Hepatol. 2002;17:526–34.PubMedCrossRef
17.
Madhu K, Avinash B, Ramakrishna B, Eapen CE, Shyamkumar NK, Zachariah U, et al. Idiopathic non-cirrhotic intrahepatic portal hypertension: common cause of cryptogenic intrahepatic portal hypertension in a Southern Indian tertiary hospital. Indian J Gastroenterol. 2009;28:83–7.PubMedCrossRef
18.
Okudaira M, Ohbu M, Okuda K. Idiopathic portal hypertension and its pathology. Semin Liver Dis. 2002;22(1):59–72.PubMedCrossRef
19.
Chang P-E, Miquel R, Blanco J-L, Laguno M, Bruguera M, Abraldes JG, et al. Idiopathic portal hypertension in patients with HIV infection treated with highly active antiretroviral therapy. Am J Gastroenterol. 2009;104:1707–14.PubMedCrossRef
20.
Schouten JN, Van der Ende ME, Koëter T, et al. Risk factors and outcome of HIV associated idiopathic noncirrhotic portal hypertension. Aliment Pharmacol Ther. 2012;36(9):875–85.PubMedCrossRef
21.
Mallet V, Blanchard P, Verkarre V, Vallet-Pichard A, Fontaine H, Lascoux-Combe C, et al. Nodular regenerative hyperplasia is a new cause of chronic liver disease in HIV-infected patients. AIDS. 2007;21:187–92.PubMedCrossRef
22.
Okuda K. Non-cirrhotic portal hypertension versus idiopathic portal hypertension. J Gastroenterol Hepatol. 2002;17(Suppl 3):S204–13.PubMed
23.
24.
Xiao X, Miao Q, Chang C, Gershwin ME, Ma X. Common variable immunodeficiency and autoimmunity—an inconvenient truth. Autoimmun Rev. 2014;13:858–64.PubMedCrossRef
25.
Bonilla FA, Barlan I, Chapel H, Costa-Carvalho BT, Cunningham-Rundles C, de la Morena MT, Espinosa-Rosales FJ, et al. International consensus document (ICON): common variable immunodeficiency disorders. J Allergy Clin Immunol Pract. 2016;4:38–59.PubMedCrossRef
26.
Resnick ES, Moshier EL, Godbold JH, Cunningham-Rundles C. Morbidity and mortality in common variable immune deficiency over 4 decades. Blood. 2012;119:1650–7.PubMedPubMedCentralCrossRef
27.
Gathmann B, Mahlaoui N, Gerard L, Oksenhendler E, Warnatz K, Schulze I, Kindle G, et al. Clinical picture and treatment of 2212 patients with common variable immunodeficiency. J Allergy Clin Immunol. 2014;134:116–26.PubMedCrossRef
28.
Cunningham-Rundles C, Maglione PJ. Common variable immunodeficiency. J Allergy Clin Immunol. 2012;129:1425-1426.e1423.PubMedCrossRef
29.
30.
Inagaki H, Nonami T, Kawagoe T, et al. Idiopathic portal hypertension associated with systemic lupus erythematosus. J Gastroenterol. 2000;35(3):235–9.PubMedCrossRef
31.
van Hoek B. The spectrum of liver disease in systemic lupus erythematosus. Neth J Med. 1996;48(6):244–53.PubMedCrossRef
32.
Matsumoto T, Yoshimine T, Shimouchi K, et al. The liver in systemic lupus erythematosus: pathologic analysis of 52 cases and review of Japanese Autopsy Registry Da-ta. Hum Pathology. 1992;23(10):1151–8.CrossRef
33.
Efe C, Purnak T, Ozaslan E, et al. Autoimmune liver disease in patients with systemic lupus erythematosus retrospective analysis of 147 cases. Scand J Gastroenterol. 2011;46(6):732–7.PubMedCrossRef
34.
Kraaijvanger R, Janssen Bonás M, Vorselaars AD, Veltkamp M. Biomarkers in the diagnosis and prognosis of sarcoidosis: current use and future prospects. Front Immunol. 2020;14(11):1443.CrossRef
35.
Kennedy PTF, Zakaria N, Modawi SB, et al. Natural history of hepatic sarcoidosis and its response to treatment. European J Gastroenterol Hepatol. 2006;18:721–6.CrossRef
36.
Bodh V, Chawla YK. Noncirrhotic intrahepatic portal hypertension. Clin Liver Dis. 2014;3:129–32.CrossRef
37.
Koukounari A, Donnelly CA, Sacko M, Keita AD, Landouré A, Dembelé R, et al. The impact of single versus mixed schistosome species infections on liver, spleen and bladder morbidity within Malian children pre- and post-praziquantel treatment. BMC Infect Dis. 2010;10:227.PubMedPubMedCentralCrossRef
38.
Mazigo HD, Nuwaha F, Wilson S, Kinung’hi SM, Morona D, Waihenya R, et al. Epidemiology and interactions of human immunodeficiency virus - 1 and Schistosoma Mansoni+ in sub-Saharan Africa. Infect Dis Poverty. 2013;2(1):2.PubMedPubMedCentralCrossRef
39.
Pereira TA, Xie G, Choi SS, Syn WK, Voieta I, Lu J, et al. Macrophage-derived hedgehog ligands promotes fibrogenic and angiogenic responses in human Schistosomiasis mansoni. Liver Int. 2013;33:149–61.PubMedCrossRef
40.
Mallet VO, Varthaman A, Lasne D, Viard JP, Gouya H, Borgel D, Lacroix-Desmazes S. et al. Acquired protein S deficiency leads to obliterative portal venopathy and to compensatory nodular regenerative hyperplasia in HIV-infected patients. AIDS. 2009;23(12):1511–1518.
41.
Lafeuillade A, Alessi MC, Poizot-Martin I, Dhiver C, Quilichini R, Aubert L, et al. Protein S deficiency and HIV infection. N Engl J Med. 1991;324:1220.PubMedCrossRef
42.
Siramolpiwat S, Seijo S, Miquel R, et al. Idiopathic portal hypertension: natural history and long-term outcome. Hepatology. 2014;59(6):2276–85.PubMedCrossRef
43.
Bora D. Epidemiology of visceral leishmaniasis in India. Natl Med J India. 1999;12:62–8.PubMed
44.
45.
Singh S, Sivakumar R. Recent advances in the diagnosis of leishmaniasis. J Postgrad Med. 2003;49:55–60.PubMedCrossRef
46.
47.
Agrawal P, Wali JP, Chopra P. Liver in kala-azar. Indian J Gastroenterol. 1990;9:135–6.
48.
Guevara P, Ramirez JL, Rojas L, Scorza JV, Gonzales N, Anez N. Leishmania braziliensis in blood 30 years after cure. Lancet. 1993;341:1341.PubMedCrossRef
49.
Rogler G. Gastrointestinal and liver adverse effects of drugs used for treating IBD. Best Practice Res Clin Gastroenterol. 2010;24(2):157–65.CrossRef
50.
Wanless IR, Godwin TA, Allen F, Feder A. Nodular regenerative hyperplasia of the liver in hematologic disorders: a possible response to obliterative portal venopathy. A morphometric study of nine cases with an hypothesis on the pathogenesis. Medicine. 1980;59:367–79.PubMedCrossRef
51.
DeLeve LD, Wang X, Kuhlenkamp JF, et al. Toxicity of azathioprine and monocrotaline in murine sinusoidal endothelial cells and hepatocytes: the role of glutathione and relevance to hepatic venoocclusive disease. Hepatology. 1996;23:589–99.PubMedCrossRef
52.
De Vito C, Tyraskis A, Davenport M, Thompson R, Heaton N, Quaglia A. Histopathology of livers in patients with congenital portosystemic shunts (Abernethy malformation): a case series of 22 patients. Virchows Arch. 2018;474(1):47–57.PubMedPubMedCentralCrossRef
53.
Baiges A, Turon F, Simón-Talero M, Tasayco S, Bueno J, Zekrini K, et al. Congenital extrahepatic portosystemic shunts (Abernethy malformation): an international observational study. Hepatology. 2019;71(2):658–69.PubMedCrossRef
54.
55.
Besmond C, Valla D, Hubert L, et al. Mutations in the novel gene FOPV are associated with familial autosomal dominant and non-familial obliterative portal venopathy. Liver Int. 2018;38(2):358–64.PubMedCrossRef
56.
Dumortier J, Boillot O, Chevallier M, et al. Familial occurrence of nodular regenerative hyperplasia of the liver: a report on three families. Gut. 1999;45(2):289–94.PubMedPubMedCentralCrossRef
57.
Witters P, Libbrecht L, Roskams T, Boeck KD, Dupont L, Proesmans M, et al. Noncirrhotic pre-sinusoidal portal hypertension is common in cystic fibrosis-associated liver disease. Hepatology. 2011;53:1064–5.PubMedCrossRef
58.
Mayer JE, Schiano TD, Fiel MI, Hoffman R, Mascarenhas JO. An association of myeloproliferative neoplasms and obliterative portal venopathy. Dig Dis Sci. 2014;59(7):1638–41.PubMedCrossRef
59.
Valla DC, Cazals-Hatem D. Vascular liver diseases on the clinical side: definitions and diagnosis, new concepts. Virchows Arch. 2018;473(1):3–13.PubMedCrossRef
60.
Schouten JNL, Nevens F, Hansen B, Laleman W, den Born M, Komuta M, et al. Idiopathic noncirrhotic portal hypertension is associated with poor survival: results of a long-term cohort study. Aliment Pharmacol Ther. 2012;35:1424–33.PubMedCrossRef
61.
Cazals-Hatem D, Hillaire S, Rudler M, Plessier A, Paradis V, Condat B, et al. Obliterative portal venopathy: portal hypertension is not always present at diagnosis. J Hepatol. 2011;54:455–61.PubMedCrossRef
62.
Carreras LO, Defreyn G, Machin SJ, Vermylen J, Deman R, Spitz B, et al. Arterial thrombosis, intrauterine death and “lupus” antiocoagulant: detection of immunoglobulin interfering with prostacyclin formation. Lancet. 1981;1:244–6.PubMedCrossRef
63.
O’Leary JG, Cai J, Freeman R, et al. Proposed diagnostic criteria for chronic antibody mediated rejection in liver allografts. Am J Transpl. 2016;16(2):603–14.CrossRef
64.
Etzion O, Koh C, Heller T. Noncirrhotic portal hypertension: An overview. Clin Liver Dis (Hoboken). 2015;6(3):72–74.
65.
Glatard AS, Hillaire S, d’Assignies G, Cazals-Hatem D, Plessier A, Valla DC, Vilgrain V. Obliterative portal venopathy: findings at CT imaging. Radiology. 2012;263(3):741–50.PubMedCrossRef
66.
67.
Elkrief L, Lazareth M, Chevret S, Paradis V, Magaz M, Blaise L, Rubbia-Brandt L, et al. Liver stiffness by transient elastography to detect porto-sinusoidal vascular liver disease with portal hypertension. Hepatology. 2020.
68.
Sarin SK, Kumar A, Chawla YK, Baijal SS, Dhiman RK, Jafri W, et al. Noncirrhotic portal fibrosis/idiopathic portal hypertension: APASL recommendations for diagnosis and treatment. Hepatol Int. 2007.
69.
Dhiman RK, Chawla Y, Vasishta RK, Kakkar N, Dilawari JB, Trehan MS, et al. Non-cirrhotic portal fibrosis (idiopathic portal hypertension): experience with 151 patients and a review of the literature. J Gastroenterol Hepatol. 2002;17:6–16.PubMedCrossRef
70.
Okuda K, Kono K, Ohnishi K, Kimura K, Omata M, Koen H, et al. Clinical study of eighty-six cases of idiopathic portal hypertension and comparison with cirrhosis with splenomegaly. Gastroenterology. 1984;86:600–10.PubMedCrossRef
71.
Rangari M, Gupta R, Jain M, Malhotra V, Sarin SK. Hepatic dysfunction in patients with extrahepatic portal venous obstruction. Liver Int. 2003;23:434–9.PubMedCrossRef
72.
Bissonnette J, Garcia-Pagán JC, Albillos A, Turon F, Ferreira C, Tellez L, et al. Role of the trans-jugular intrahepatic portosystemic shunt in the management of severe complications of portal hypertension in idiopathic noncirrhotic portal hypertension: liver failure/cirrhosis/portal hypertension. Hepatology. 2016;64(1):224–31.PubMedCrossRef
73.••
Lattanzi B, Gioia S, Di Cola S, et al. Prevalence and impact of sarcopenia in non-cirrhotic portal hypertension. Liver Int. 2019;39(10):1937–42. Of major importance: This report notes that the prevalence of sarcopenia in a cohort of patients with non-cirrhotic portal hypertension as assessed by skeletal muscle index (SMI) was similar to those with cirrhosis, decompensated and portal vein thrombosis suggesting that the presence of portal hypertension contributes sarcopenia. In addition, sarcopenia was also associated with a higher rate of variceal bleeding requiring TIPS placement.PubMedCrossRef
74.
Dhiman RK, Behera A, Chawla YK, Dilawari JB, Suri S. Portal hypertensive biliopathy. Gut. 2007;56:1001–8.PubMedCrossRef
75.
Dilawari JB, Chawla YK. Extrahepatic portal venous obstruction. Gut. 1988;29:L554-555.CrossRef
76.
Maruyama H, Okugawa H, Kobayashi S, Yoshizumi H, Takahashi M, Ishibashi H, et al. Non-invasive porto-graphy: a microbubble-induced three-dimensional sonogram for discriminating idiopathic portal hypertension from cirrhosis. Br J Radiol. 2012;85(1013):587–95.PubMedPubMedCentralCrossRef
77.
Lee H, Ainechi S, Singh M, Ells PF, Sheehan CE, Lin J. Histological spectrum of idiopathic noncirrhotic portal hypertension in liver biopsies from dialysis patients. Int J Surg Pathol. 2015;23(6):439–46.PubMedCrossRef
78.
Bioulac-Sage P, Le Bail B, Bernard PH, Balabaud C. Hepatoportal sclerosis. Semin Liver Dis. 1995;15(4):329–39.PubMedCrossRef
79.
Jharap B, van Asseldonk DP, de Boer NKH, et al. Diagnosing nodular regenerative hyperplasia of the liver is thwarted by low interobserver agreement. PLoS ONE. 2015;10:e0120299.PubMedPubMedCentralCrossRef
80.
de Franchis R; On behalf of the Baveno V Faculty. Revising consensus in portal hypertension: report of the Baveno V consensus workshop on methodology of diagnosis and therapy in portal hypertension. J Hepatol. 2010;53:762–768.
81.
Sarin SK, Gupta N, Jha SK, Agrawal A, Mishra SR, Sharma BC, et al. Equal efficacy of endoscopic variceal ligation and propranolol in preventing variceal bleeding in patients with noncirrhotic portal hypertension. Gastroenterology. 2010;139:1238–45.PubMedCrossRef
82.
Sarin SK, Sollano JD, Chawla YK, Amarapurkar D, Hamid S, Hashizume M, et al. Members of the APASL working party on portal hypertension. Consensus on extra-hepatic portal vein obstruction. Liver Int. 2006;26:512–9.PubMedCrossRef
83.
Romano M, Giojelli A, Capuano G, Pomponi D, Salvatore M. Partial splenic embolization in patients with idiopathic portal hypertension. Eur J Radiol. 2004;49:268–73.PubMedCrossRef
84.
Hirota S, Ichikawa S, Matsumoto S, Motohara T, Fukuda T, Yoshikawa T. Interventional radiologic treatment for idiopathic portal hypertension. Cardiovasc Intervent Radiol. 1999;22:311–4.PubMedCrossRef
85.
Krasinskas AM, Eghtesad B, Kamath PS, Demetris AJ, Abraham SC. Liver transplantation for severe intrahepatic noncirrhotic portal hypertension. Liver Transpl. 2005;11:627–34.PubMedCrossRef
86.
Dumortier J, Bizollon T, Scoazec JY, Chevallier M, Bancel B, Berger F, et al. Orthotopic liver transplantation for idiopathic portal hypertension: indications and outcome. Scand J Gastroenterol. 2001;36:417–22.PubMedCrossRef
87.
Loinaz C, Colina F, Musella M, Lopez-Rios F, Gomez R, Jimenez C, et al. Orthotopic liver transplantation in 4 patients with portal hypertension and non-cirrhotic nodular liver. Hepato-Gastroenterol. 1998.
Metadata
Title
Systemic Disease and Portal Hypertension
Authors
Talal Khurshid Bhatti
Paul Y. Kwo
Publication date
04-03-2024
Publisher
Springer US
Published in
Current Hepatology Reports / Issue 1/2024
Electronic ISSN: 2195-9595
DOI
https://doi.org/10.1007/s11901-024-00645-8

Other articles of this Issue 1/2024

Current Hepatology Reports 1/2024 Go to the issue

ReviewPaper

Prophylaxis and Treatment of Bacterial Infections in Cirrhosis

ReviewPaper

Cholestatic Pruritus: Pathophysiology, Current Management Approach, and Emerging Therapies

ReviewPaper

Endocrinology for the Hepatologist

ReviewPaper

Novel Blood-Based Biomarkers for HCC

ReviewPaper

Portal Vein Thrombosis in Patients with Cirrhosis

ReviewPaper

Should Indications for Antiviral Therapy for Hepatitis B Be Broadened to Include Immune-Tolerant Patients, Inactive Carriers, or Patients in the “Gray Zone”?
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits